[HTML][HTML] Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma
UH Gandhi, W Senapedis, E Baloglu, TJ Unger… - … Myeloma and Leukemia, 2018 - Elsevier
Multiple myeloma (MM) is a malignancy of plasma cells that is typically chronic, and relapse
is common. Current therapeutic strategies include combination and sequential treatments …
is common. Current therapeutic strategies include combination and sequential treatments …
[HTML][HTML] E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1
B Kwanten, T Deconick, C Walker, F Wang… - Biomedicine & …, 2023 - Elsevier
Abstract Selinexor (KPT-330), a small-molecule inhibitor of exportin-1 (XPO1, CRM1) with
potent anticancer activity, has recently been granted FDA approval for treatment of …
potent anticancer activity, has recently been granted FDA approval for treatment of …
Selinexor for advanced hematologic malignancies
JS Walker, R Garzon, R Lapalombella - Leukemia & Lymphoma, 2020 - Taylor & Francis
Recent measures to classify novel molecular targets with therapeutic potential across
multiple hematologic tumors have identified the eukaryotic nuclear exporter, exportin 1 …
multiple hematologic tumors have identified the eukaryotic nuclear exporter, exportin 1 …
Clinical utility of selinexor/dexamethasone in patients with relapsed or refractory multiple myeloma: a review of current evidence and patient selection
P Malandrakis, I Ntanasis-Stathopoulos… - OncoTargets and …, 2020 - Taylor & Francis
Multiple myeloma (MM) is one the most common hematological malignancies, and despite
the survival prolongation offered by proteasome inhibitors (PIs), immunomodulatory drugs …
the survival prolongation offered by proteasome inhibitors (PIs), immunomodulatory drugs …
Selective inhibitors of nuclear export (SINEs) in myeloma: breakthrough or bust?
T Nishihori, R Baz - Expert Opinion on Drug Safety, 2020 - Taylor & Francis
Selinexor, the first in class for selective inhibitor of nuclear export (SINE), was approved by
the Food and Drug Administration (FDA) for relapsed/refractory myeloma on 3 July, 2019 to …
the Food and Drug Administration (FDA) for relapsed/refractory myeloma on 3 July, 2019 to …